Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,435 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level B Clear all
Completed Phase 1 Interventional Results available

Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma

NCT02215967
View directory record Official record
Conditions
Myeloma, Plasma-Cell, Myeloma-Multiple
Interventions
Cyclophosphamide, Fludarabine, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 73 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

NCT05451212
View directory record Official record
Conditions
MuSK Myasthenia Gravis
Interventions
MuSK-CAART
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Orange, California • Sacramento, California • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 26, 2026, 2:08 PM EDT
Terminated Phase 3 Interventional Results available

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

NCT00562965
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
inotuzumab ozogamicin, rituximab, cyclophosphamide, vincristine, prednisone/prednisolone, mitoxantrone, fludarabine, dexamethasone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
17
States / cities
Mission Hills, California • Evansville, Indiana • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 26, 2026, 2:08 PM EDT
Recruiting Not applicable Interventional

Microrandomized Trial to Optimize Use of Burden-reducing Self-monitoring Approaches in Behavioral Obesity Treatment

NCT07228130
View directory record Official record
Conditions
Obesity & Overweight
Interventions
Online Behavioral Obesity Treatment, Full Dietary Self-monitoring, Reduced-frequency Dietary Self-monitoring, Self-Monitoring of Dietary Lapses Only, Smartwatch-based Self-monitoring of Energy Intake, Self-monitoring of Body Weight Only
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 26, 2026, 2:08 PM EDT
Enrolling by invitation Not applicable Interventional

Evaluation of Violence Prevention Strategies to Prevent and Reduce Community Levels of Youth Violence

NCT06176300
View directory record Official record
Conditions
Violence, Exposure to Violent Event, Adolescent Behavior
Interventions
PAR - the SEED Method, PAR-Youth Voices, Emerging Leaders hospital-based intervention
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
12 Years and older
Enrollment
3,390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

NCT02471911
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
KPT-330, Rituximab, Etoposide, Carboplatin, Ifosfamide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 26, 2026, 2:08 PM EDT
Not listed Not applicable Interventional

Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)

NCT03661034
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Dementia, Mild Cognitive Impairment, Memory Disorders, Memory Loss, Memory Impairment, Memory Disorders, Age Related, Alzheimer Disease, Late Onset, Cognitive Impairment, Dementia, Mild, Dementia, Alzheimer Type, Cognitive Decline
Interventions
GammaSense Stimulation System (non-invasive, non-significant risk)
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults

NCT07261371
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Test formulation (Treatment A), Reference formulation (Treatment B), Test formulation (Treatment C), Test formulation (Treatment D)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Development and Validation of a Multi-Mineral Fluoride Mouthrinse

NCT00642252
View directory record Official record
Conditions
Dental Caries
Interventions
Fluoride
Drug
Lead sponsor
Indiana Nanotech, LLC
Other
Eligibility
13 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

NCT04994106
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5462, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

NCT02622334
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Placebo, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People

NCT04863287
View directory record Official record
Conditions
Lyme Disease
Interventions
2217LS, 0.9% Sodium Chloride (NaCl)
Biological · Other
Lead sponsor
MassBiologics
Other
Eligibility
19 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dysregulation of FSH in Obesity: Functional and Statistical Analysis

NCT02478775
View directory record Official record
Conditions
Obesity, Fertility
Interventions
Degarelix (GnRH antagonist), recombinant FSH, Cetrorelix
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 39 Years · Female only
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 26, 2026, 2:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

NCT06660667
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
SAR402663, Diluent
Biological · Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years to 90 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
24
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 26, 2026, 2:08 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants

NCT07242781
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986365, Itraconazole, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 26, 2026, 2:08 PM EDT
Active, not recruiting Phase 1 Interventional

Multi-antigen T Cell Infusion Against Neuro-oncologic Disease

NCT03652545
View directory record Official record
Conditions
Brain Tumor
Interventions
TAA-T
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
6 Months to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Continuous Glucose Monitoring in Prediabetes With Health Education Videos Among Community Health Workers

NCT06883812
View directory record Official record
Conditions
Prediabetes
Interventions
CGM
Device
Lead sponsor
David S Black, PhD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 26, 2026, 2:08 PM EDT
Active, not recruiting Phase 1 Interventional

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT05052528
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate, Rituximab
Biological · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants

NCT04713553
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2, BNT162b2.B.1.351
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
12 Years to 50 Years
Enrollment
1,574 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
17
States / cities
Oakland, California • Milford, Connecticut • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 26, 2026, 2:08 PM EDT
Terminated Not applicable Interventional

The Effect of Ribose on B-Type Natriuretic Peptide (BNP) Levels in Congestive Heart Failure Patients

NCT00329485
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
CORvalen (D-Ribose)
Drug
Lead sponsor
Valen Labs
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2007 · Synced Oct 26, 2026, 2:08 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

NCT04569786
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
V590, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
7
States / cities
Tempe, Arizona • Miami, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Not applicable Interventional

Study to Evaluate ACB Versus FNB Early Postoperative Period Functional Outcomes After TKA

NCT02218814
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Nerve Block
Interventions
Adductor Canal Block, Bupivacaine, Femoral Nerve Block, Bupivacaine
Procedure
Lead sponsor
George Macrinici
Other
Eligibility
40 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Joliet, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery

NCT04238481
View directory record Official record
Conditions
Laparoscopic/Minimally Invasive Colorectal Surgery
Interventions
Pudexacianinium chloride
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Orlando, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 26, 2026, 2:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

NCT00520130
View directory record Official record
Conditions
Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia, Multiple Myeloma
Interventions
Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT), Conditioning Chemotherapy, TMS, FLAG, EPOCH-F, Alemtuzumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 74 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 26, 2026, 2:08 PM EDT